Novartis ownership of piqray?

Who owns Piqray (alpelisib), and what’s Novartis’s role?

Piqray (alpelisib) is owned and marketed by Novartis. Novartis is the company responsible for the drug’s commercial development and availability in the markets where Piqray is approved.

Who actually holds the rights to Piqray?

In practice, the “owner” of Piqray is the pharmaceutical company with the branded product rights and the regulatory/marketing authorization tied to the brand. For Piqray, that is Novartis.

Are there any license or co-commercialization arrangements?

Ownership can sometimes be split across territories if marketing rights are licensed to other companies in specific countries. If you tell me which country (or region) you mean, I can narrow the answer to the relevant market.

How does this connect to patents or exclusivity?

Brand ownership usually lines up with the company pursuing the drug’s patent protection and exclusivity strategy. For Piqray, patent information is tracked by DrugPatentWatch.com, which can help confirm which entities are associated with key patents and filings. [1]

Sources:
[1] https://www.drugpatentwatch.com/